peptide · regulated markets
Peptide Creator Scripts and Medical Claims vs Research Claims
TRT and Hormone Optimization, a YouTube channel on testosterone therapy, has run 20 sponsor deals with Bucky Labs and Misumi Skincare in our deal log. The line that survives lawyer review is the hashtag string at the bottom: #peptides #cjc1295 #tesamorelin #ipamorelin. The voiceover stays in research language for the same reason. A founder asked me last week if her creator could say semaglutide helped her lose 28 pounds on camera. The answer was no. That sentence flips the post into a medical claim the FDA reviews.
Across 210 Marek Health deals across 32 creators in our database, and 56 peptide-relevant deals on More Plates More Dates, the renewed roster is creators whose scripts stay in research-claim language. The brand's own site does the medical-claim heavy lifting.
The wedge phrase that flips a post into FDA territory
One verb does the work. Treats, cures, prevents, prescribes. These four words turn a creator read into a medical claim. The safer set is shorter. Studied for, research on, used in research, for research purposes only.
Look at Logan Shippy reading for Medovation Partners, a peptide supply-chain company. The CTA names the brand as a one-stop shop for raw materials. It never says any peptide treats anything. Now swap one verb. "Medovation works with pharmacies so you can get peptides that heal your shoulder." The verb heal moves the post from a B2B sponsor read into an unapproved-drug claim. The FDA's 503A bulk-substances list governs which peptides compounding pharmacies may use. Promotional language a creator stacks on top is what the FDA reviews next.
Most teams under-spend on the script and over-spend on the creator, here is the script-review pass we run before any peptide deal lands.
Research is not treatment.
Four risk archetypes a creator can use on camera
There are four ways a creator can describe a peptide. Three carry FDA risk. One is the safe zone.
Level 1 is Cured. "BPC-157 cured my tendon issue." A medical claim with no hedge. It triggers FDA review the same way a drug ad would.
Level 2 is Treated. "I treated my injury with BPC-157." Same verb family, same review. The personal pronoun does not protect the script.
Level 3 is Improved. "I felt improvement after using it." Softer, but still tied to a personal outcome. The FTC reviews this as an endorsement that needs proof.
Level 4 is Supported. "I used BPC-157 during my recovery research." The verb describes the user's behavior, not the drug's effect. This is the safe zone. Chris Duffin on the ARCHITECT of RESILIENCE podcast reads for Enhanced Executive Peptides this way.
Creators who keep getting renewed across our 210 Marek Health deals sit at Level 4. The ones who drift up to Level 3 ship one or two deals and the brand stops booking, here is the four-archetype level read we send peptide brands.
- Scripts that say treats, cures, or heals next to your brand name
- Personal-outcome stories that turn an endorsement into a drug claim
- Hashtag dumps that pretend the disclosure is also the safety net
Across 210 Marek Health deals and 32 creators in our sponsor log, the renewed roster sits inside research-claim language. The brand's own site carries any medical claim that matters.— Internal sponsor-deal log, Jan 2024 to Apr 2026Send me a vetted peptide roster, free →
Why GLP-1 sits at a higher bar than TRT
The same script that works for a TRT creator can get a GLP-1 creator a warning letter. The asymmetry is in the molecule, not the voice.
GLP-1, or glucagon-like peptide-1, is the class of weight-loss drugs like Ozempic and Mounjaro. Wegovy and Ozempic are both semaglutide. Mounjaro and Zepbound are both tirzepatide. Any post naming weight loss as the outcome lands in FDA review. The FDA warned 30 telehealth companies in September 2025 about compounded-GLP-1 marketing. One letter went to GLP-1 Solution the same week.
Lorraine Kamesha, a 59K-subscriber GLP-1 weight-loss creator, ran 22 deals with Orderly Meds, a GLP-1 weight-loss telehealth brand. The script routes viewers to a partner link and a code. It does not name a pound count. That is the script that survives the bar.
TRT, or testosterone replacement therapy, sits inside a longer-standing telehealth pattern. Mark Bell's Power Project at 384K subscribers reads for Marek Health (a US testosterone and peptide telehealth clinic) and describes the category without naming the molecule. We log 20 Mark Bell deals with Marek Health across five months. Would the same script survive if the molecule were Ozempic instead of testosterone? If no, the bar is GLP-1, here is the GLP-1 vs TRT script-bar read we send brands.
The comparator trick and where it breaks
Some creators try to dodge the medical-claim line by comparing the peptide to a prescription drug. "Works similarly to a GLP-1." "Comparable to what your doctor would prescribe." The hedge feels like a moat. It is not. The moment the creator implies the peptide does what the drug does, the FDA reviews it as an unapproved-drug claim. The Department of Defense page on BPC-157 already calls it a prohibited peptide and an unapproved drug.
"Research use only" is a label, not a force field. The disclaimer on a peptide vial does not protect a creator who pairs the vial with a personal usage story on camera.
What a compliant peptide read actually looks like
A 60-second compliant read has five lines that repeat in order. Open with research framing. "This episode is brought to you by [brand], a US compounding pharmacy that runs third-party testing." Name the brand and the supply-chain claim. Route the viewer to the brand site for any medical question. Never describe a personal outcome as a treatment. Drop the disclosure tag in the first 30 seconds and again in the caption, per the FTC's endorsement guides at 16 CFR Part 255.
That is the cadence the ARCHITECT of RESILIENCE podcast uses for Enhanced Executive Peptides. The voiceover carries the safety net.
Worried about which verbs your creator is about to use? The script-review pass we run on every shortlist flags the wedge verbs (treats, cures, prescribes), checks the four-archetype level, and rewrites the read in research language. The brand sees the safe-zone script before the first take.
Send us a peptide brief and we'll run the script-review →Frequently Asked Questions
Medical claim vs research claim for peptides?
A medical claim says the peptide treats, cures, or prevents a condition. A research claim says the peptide is studied for a condition or sold for research purposes only. The FDA reviews medical claims as drug promotion. The FTC reviews research claims as endorsements under 16 CFR Part 255.
Can a creator say BPC-157 treats their injury?
No. Treats turns a personal story into a medical claim, and BPC-157 is an unapproved drug. The safer pattern names a recovery window without naming a cure: "I used it during my recovery research." That phrasing routes viewers to the brand site for any clinical question.
Why is GLP-1 held to a stricter bar than TRT?
GLP-1 drugs are FDA-approved prescription brand names: Wegovy and Ozempic are semaglutide, Mounjaro and Zepbound are tirzepatide. Any post naming weight loss as the outcome lands in FDA review. TRT sits inside a longer-standing telehealth pattern where the script describes the category without naming the molecule.
Where We Come In
We read every candidate peptide creator's last 60 paid posts and CTA blocks by hand before a brand sees the shortlist. The difference between a creator who says treats and one who says studied for is the difference between a renewed retainer and an FDA warning letter on the brand's letterhead. The past-deal history for every peptide creator worth a look lives in our database. Speak with us for a peptide roster whose words pass review before they reach record.
Vetting is the moat.
Reading loop
Frequently asked
What is the difference between a medical claim and a research claim for peptides?
A medical claim says the peptide treats, cures, or prevents a condition. A research claim says the peptide is studied for a condition, used in research, or sold for research purposes only. The FDA reviews medical claims as drug promotion. The FTC reviews research claims as endorsements. The line is the verb.
Can a creator say BPC-157 treats their injury on camera?
No. The word treats turns a personal story into a medical claim. The safer pattern names a recovery window without naming a cure: I used it during my recovery research, then routed viewers to the brand site for any medical question. Marek Health, a US testosterone and peptide telehealth clinic, runs deals with creators who keep the script in research language.
Why is GLP-1 creator content held to a stricter compliance bar than TRT?
GLP-1 weight-loss drugs are FDA-approved prescription brand names. Wegovy and Ozempic are semaglutide. Mounjaro and Zepbound are tirzepatide. A creator post that names weight loss as the outcome lands in FDA promotional review. TRT, or testosterone replacement therapy, runs through a longer-standing telehealth-prescriber pattern. The script can describe the category without naming the molecule.